Cresco Labs (CNSX:CL) - Aandelenkoers, Nieuws & Analyse

CL Overzicht aandelen

Cresco Labs Inc. kweekt, produceert en verkoopt samen met haar dochterondernemingen cannabisproducten voor de detailhandel en medicinale cannabisproducten in de Verenigde Staten.

Over het bedrijf

CL fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

Trading at 81% below our estimate of its fair value

Revenue is forecast to grow 7.09% per year

Trading at good value compared to peers and industry

Risicoanalyse

Significant insider selling over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Cresco Labs Inc. Concurrenten

Cronos Group

TSX:CRON

CA$1.2b

Knight Therapeutics

TSX:GUD

CA$570.5m

Cipher Pharmaceuticals

TSX:CPH

CA$389.9m

Verano Holdings

NEOE:VRNO

CA$1.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Cresco Labs
Historische aandelenkoersen
Huidige aandelenkoers	CA$2.14
52 Week Hoogtepunt	CA$3.58
52 Week Laag	CA$1.52
Bèta	1.97
11 maand verandering	-4.04%
3 maanden verandering	5.94%
1 Jaar Verandering	37.18%
33 jaar verandering	-80.89%
5 jaar verandering	-74.82%
Verandering sinds IPO	-67.33%

Recent nieuws en updates

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Oct 24

Recent updates

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Oct 24

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Jul 17

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Jun 19

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 19

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04

Rendement voor aandeelhouders

	CL	CA Pharmaceuticals	CA Markt
7D	-2.7%	-4.7%	-1.5%
1Y	37.2%	17.0%	21.1%

Rendement versus industrie: CL exceeded the Canadian Pharmaceuticals industry which returned 17.1% over the past year.

Rendement versus markt: CL exceeded the Canadian Market which returned 20.8% over the past year.

Prijsvolatiliteit

Is CL's price volatile compared to industry and market?
CL volatility
CL Average Weekly Movement	10.1%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.5%
10% least volatile stocks in CA Market	2.9%

Stabiele aandelenkoers: CL has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatiliteit in de loop van de tijd: CL's weekly volatility (10%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1990	2,900	Charlie Bachtell	www.crescolabs.com

Cresco Labs Inc. kweekt, produceert en verkoopt samen met haar dochterondernemingen cannabisproducten voor de detailhandel en medische toepassingen in de Verenigde Staten. Het bedrijf levert cannabis in de vorm van bloemen, vape pennen, levende harsen, wegwerppennen en extracten onder de merknaam Cresco; vape carts, vape pennen, bloem, popcorn, shake, pre-rolls, shorties en concentraten onder de merknaam High Supply; vapes en gummies onder de merknaam Good News; vapes en edibles onder de merknaam Wonder Wellness Co; en tincturen, capsules, zalven en sublinguale oliën onder de merknaam Remedi. Het bedrijf biedt ook cannabisbloemen aan onder het merk FloraCal; en chocolade- en toffeeconfecties en fruitgummies onder het merk Mindy's Edibles, en heeft licenties voor het merk Kiva, dat met cannabis geïnfuseerde edibles produceert, waaronder chocoladeconfecties, gummies, mints en taartjes.

Cresco Labs Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Cresco Labs zich tot de beurswaarde?
CL fundamentele statistieken
Marktkapitalisatie	CA$943.01m
Inkomsten(TTM)	-CA$240.69m
Inkomsten(TTM)	CA$1.03b

0.7x

P/S-verhouding

-3.1x

Koers/Winstverhouding

Is CL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CL resultatenrekening (TTM)
Inkomsten	US$734.82m
Kosten van inkomsten	US$370.67m
Brutowinst	US$364.15m
Overige uitgaven	US$536.61m
Inkomsten	-US$172.46m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 08, 2024

Winst per aandeel (EPS)	-0.50
Brutomarge	49.56%
Nettowinstmarge	-23.47%
Schuld/Eigen Vermogen Verhouding	111.2%

Hoe presteerde CL op de lange termijn?

Bekijk historische prestaties en vergelijking

CL Overzicht aandelen

Beloningen

Risicoanalyse

Cresco Labs Inc. Concurrenten

TSX:CRON

CA$1.2b

TSX:GUD

CA$570.5m

TSX:CPH

CA$389.9m

NEOE:VRNO

CA$1.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Cresco Labs Inc. to Report Q3, 2024 Results on Nov 08, 2024

Cresco Labs Inc. Announces Resignation of Tarik Brooks as Board of Directors

Cresco Labs Inc. Announces CFO Changes

New minor risk - Profitability

No longer forecast to breakeven

Recent updates

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Cresco Labs Inc. to Report Q3, 2024 Results on Nov 08, 2024

Cresco Labs Inc. Announces Resignation of Tarik Brooks as Board of Directors

Cresco Labs Inc. Announces CFO Changes

New minor risk - Profitability

No longer forecast to breakeven

Co-Founder & Independent Director recently sold CA$110k worth of stock

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023)

Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Co-Founder & Independent Director recently sold CA$236k worth of stock

New minor risk - Shareholder dilution

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$364k worth of stock

First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023)

Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million.

Consensus EPS estimates upgraded to US$0.055 loss

Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024

Cresco Labs Inc., Annual General Meeting, Jun 10, 2024

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.059 loss

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

New minor risk - Profitability

Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Chief Financial Officer exercised options to buy CA$150k worth of stock.

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024

Cresco Labs Inc. Promotes Greg Butler to the Position of President

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

New minor risk - Shareholder dilution

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 91%, revenue upgraded

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022)

Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023

New major risk - Share price stability

Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc.

No longer forecast to breakeven

Is Cresco Labs (CSE:CL) Using Too Much Debt?

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 42%

Chief Financial Officer recently bought CA$149k worth of stock

Price target decreased by 8.4% to CA$4.80

Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022)

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023

Insufficient new directors

Consensus EPS estimates fall by 15%

Price target decreased by 36% to CA$3.82

First quarter 2023 earnings released: US$0.092 loss per share (vs US$0.094 loss in 1Q 2022)

Cresco Labs Inc. to Report Q1, 2023 Results on May 24, 2023

Consensus EPS estimates fall by 40%